Dec 19, 2024
|
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Primary statistical analysis of overall survival compared TA-TMA patients treated with narsoplimab in its pivotal trial to a cohort of over 100 TA-TMA patients not treated with narsoplimab in an external control stem cell transplant registry; FDA-agreed analysis was conducted by an independent
|
|
Dec 10, 2024
|
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
-- Clinical Trial and Clinical Pharmacology Data Support Upcoming Enrollment of Omeros’ Zaltenibart Phase 3 Clinical Program in PNH -- SEATTLE --(BUSINESS WIRE)--Dec. 10, 2024-- Omeros Corporation (Nasdaq: OMER) today announced that two posters directed to zaltenibart (OMS906), Omeros’
|
|
Dec 02, 2024
|
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
-- Presentations Highlight Progress in Late-Stage Development of Lead MASP-3 Inhibitor Zaltenibart -- SEATTLE --(BUSINESS WIRE)--Dec. 2, 2024-- Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart (OMS906), Omeros’ investigational inhibitor of MASP-3, the key
|
|
Nov 21, 2024
|
Omeros Corporation Provides Update on Progress Toward BLA Resubmission
SEATTLE --(BUSINESS WIRE)--Nov. 21, 2024-- Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its biologics license application (“BLA”) for narsoplimab, the company’s first-in-class antibody targeting MASP-2, the effector enzyme of the lectin
|
|
Nov 13, 2024
|
Omeros Corporation Reports Third Quarter 2024 Financial Results
– Conference Call Today at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--Nov. 13, 2024-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2024 , which include: Net loss for the third quarter of 2024
|
|
Nov 11, 2024
|
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024
SEATTLE --(BUSINESS WIRE)--Nov. 11, 2024-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024 , on Wednesday, November 13, 2024 , after the market closes. Omeros management will host a conference call and
|
|
Oct 24, 2024
|
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
-- Phase 3 Studies on the Horizon in both PNH and C3G -- SEATTLE --(BUSINESS WIRE)--Oct. 24, 2024-- Omeros Corporation today announced that zaltenibart (OMS906) has received rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for the treatment of complement 3
|
|
Aug 07, 2024
|
Omeros Corporation Reports Second Quarter 2024 Financial Results
– Conference Call Today at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--Aug. 7, 2024-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications
|
|
Aug 05, 2024
|
Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024
SEATTLE --(BUSINESS WIRE)--Aug. 5, 2024-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2024 , on Wednesday, August 7, 2024 , after the market closes. Omeros management will host a conference call and webcast that
|
|
Jun 04, 2024
|
Omeros Announces Webcast Details for Annual Meeting of Shareholders
SEATTLE --(BUSINESS WIRE)--Jun. 4, 2024-- Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, June 6, 2024 , starting at 10:00 a.m. Pacific Time .
|
|
Jun 03, 2024
|
Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028
$118.1 million , or 55%, of outstanding convertible notes due in 2026 repurchased at approximately 75% of notional value, resulting in $51 million in total debt extinguishment Repurchase funded from new $67 million secured four-year term loan maturing in June 2028 together with $21 million cash on
|
|
May 15, 2024
|
Omeros Corporation Reports First Quarter 2024 Financial Results
– Conference Call Today at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--May 15, 2024-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications
|
|
May 10, 2024
|
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
SEATTLE --(BUSINESS WIRE)--May 10, 2024-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended March 31, 2024 , on Wednesday, May 15, 2024 , after the market closes. Omeros management will host a conference call and
|
|
May 09, 2024
|
Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
-- Interim Analysis Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation -- SEATTLE --(BUSINESS WIRE)--May 9, 2024-- Omeros Corporation (Nasdaq: OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in
|
|
Apr 01, 2024
|
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
– Conference Call Today at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--Apr. 1, 2024-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications
|
|
Mar 27, 2024
|
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
SEATTLE --(BUSINESS WIRE)--Mar. 27, 2024-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023 , on Monday, April 1, 2024 , after the market closes. Omeros management will host a conference call and
|
|
Feb 20, 2024
|
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
SEATTLE --(BUSINESS WIRE)--Feb. 20, 2024-- Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
|
|
Feb 01, 2024
|
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
– Expands DRI royalty deal on U.S. net sales of OMIDRIA – – Expanded deal brings Omeros $115 million upfront payment and opportunity for additional $55 million in sales-based milestones – SEATTLE --(BUSINESS WIRE)--Feb. 1, 2024-- Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI
|
|